Business Context and Reporting Period
Company: Disc Medicine, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2024
Reporting Period: Single event date (November 15, 2024)
Disc Medicine, Inc., a Delaware corporation, filed this report to disclose the entry into a new material definitive agreement for equity sales and the termination of a prior sales agreement.
Key Financial Metrics and Transaction Details
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The financial data provided relates specifically to the equity offering agreements:
- New Offering Capacity: Up to $200.0 million in aggregate offering price under the new agreement with Cantor Fitzgerald & Co.
- Commission Rate: Up to 3.0% of gross proceeds for the new agreement.
- Prior Agreement Proceeds: $22.5 million in aggregate gross proceeds from 376,363 shares sold under the terminated agreement with Jefferies LLC.
- Termination Penalties: None.
Material Changes Versus Prior Period
The primary material change is the replacement of the company's equity sales agent and the associated sales agreement:
- Termination: The "Open Market Sale Agreement" with Jefferies LLC, originally dated October 10, 2023, was terminated effective November 15, 2024.
- New Agreement: A "Controlled Equity Offering SM Sales Agreement" was entered into with Cantor Fitzgerald & Co. on November 15, 2024.
- Registration Statement: The new offering utilizes a different effective registration statement on Form S-3 (No. 333-281359) compared to the prior agreement (File No. 333-275652).
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing indicates the Company is not obligated to make any sales of shares under the new agreement. Sales will be made at the Company's sole discretion, potentially subject to price or size limits. The agreement allows for sales as an "at the market" offering or as principal transactions.
Risks and Contingencies:
- Dilution Risk: The issuance of up to $200.0 million in new shares may dilute existing shareholders.
- Market Conditions: Sales are subject to market conditions and the Company's discretion; no sales are guaranteed.
- Legal Liability: The Company has agreed to indemnify Cantor Fitzgerald against certain liabilities under the Securities Act and the Securities Exchange Act of 1934.
Unusual Items: None reported beyond the standard terms of an equity sales agreement.
Investor Verification Checklist
- Verify the current share price and potential dilution impact of a $200.0 million offering.
- Review the full text of the Controlled Equity Offering Sales Agreement (Exhibit 1.1) for specific termination clauses and covenants.
- Confirm the status of the Company's cash position and burn rate to assess the necessity of immediate capital raising.
- Check for any subsequent filings regarding the actual sale of shares under the new Cantor Fitzgerald agreement.